slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 200,251-200,280
Pages 10,126
Rows per page 30
Component
200,251-200,280 of 303,780
26
The slide presents two side-by-side tables for different fiscal periods, detailing segment revenue/EBITDA and the specific adjustments used to calculate non-GAAP adjusted EBITDA.Benson Hill | Results Presentation Deck | 27 slides · Benson Hill
Conference presentation Investor relations Beat · Action1 hit
27
The slide presents two separate reconciliation tables side-by-side for 2022 estimates.Benson Hill | Results Presentation Deck | 27 slides · Benson Hill
Conference presentation Investor relations Beat · Action1 hit
01
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
02
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
03
The slide uses a linked-circle diagram to represent the company's core value propositions.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a 2x5 grid layout to display 10 team members.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Team1 hit
05
The slide uses a comparative visual framework to contrast healthy cells (no binding) with cancer cells (CAB binding).BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a Gantt-style visualization to show the progression of drug candidates through clinical phases.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
08
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
09
Uses a comparative framework to highlight unmet medical needs in two specific cancer indications.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
10
Includes waterfall plot for partial response and spider plot for longitudinal tumor change.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
11
The slide uses a process-flow diagram to map patient cohorts to clinical outcomes and subsequent study advancement decisions.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
12
Includes a spider plot for lesion change and a Kaplan-Meier survival curve.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
13
Includes Kaplan-Meier survival curve and waterfall plot for lesion change.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
14
Clinical trial data showing PFS at 3 months for Liposarcoma and Synovial Sarcoma cohorts.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
16
The slide uses a grid of metrics to establish the total addressable market and clinical benchmarks.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
17
The chart is a waterfall plot showing maximum change from baseline for different patient cohorts.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The slide uses a process-oriented layout to describe clinical trial phases.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
The slide serves as a section divider for a deep dive into a specific therapeutic platform.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
22
The slide uses a grid of metrics to define the total addressable market and the specific target segment.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
23
The chart is a waterfall plot showing percentage change in tumor size for individual patients.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
24
The slide uses a 2x2 grid of metrics to frame the market problem, followed by specific target population and success threshold data.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
26
SCCHN = Squamous Cell Carcinoma of the Head and Neck. ROR2 is the target biomarker.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
27
The slide uses a table to present clinical outcomes for specific tumor types, emphasizing the first-in-class potential of the therapy.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
29
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
32
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
33
The chart shows tumor volume over time for three different antibody treatments, with the CAB-EpCAM x CAB-CD3 showing the best efficacy.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
34
The slide uses a timeline-based table structure to map programs to specific clinical milestones.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Loop · Why Now1 hit
35
Uses a linked-circle diagram to represent interconnected business pillars.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
36
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit